Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug

Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug

Evgen Pharma PLC (LON:EVG) Chief Executive Dr Huw Jones talks to Proactive London following an abundance of news from the clinical-stage drug development company. Jones talks through the ‘STAR’ trial updates which now have a total of 56 patients in Dundee. The aim is to reach 100 patients, which will be assessed with acute respiratory infections, including those with coronavirus (COVID-19). Specifically, researchers will investigate whether SFX-01 can reduce the severity, or prevent the onset of acute respiratory distress syndrome (ARDS) in pneumonia patients.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK